Sangamo BioSciences Inc. (NASDAQ:SGMO) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $4.46 and last traded at $4.48, with a volume of 739,610 shares changing hands. The stock had previously closed at $4.57.

SGMO has been the subject of several analyst reports. Wells Fargo & Co. initiated coverage on shares of Sangamo BioSciences in a research note on Tuesday, May 3rd. They issued a “buy” rating for the company. Jefferies Group reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Sangamo BioSciences in a research note on Thursday, June 9th. Cowen and Company reaffirmed a “buy” rating on shares of Sangamo BioSciences in a research note on Wednesday. Janney Montgomery Scott lowered shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $15.00 to $8.00 in a research note on Thursday, August 4th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Sangamo BioSciences in a research note on Friday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $15.58.

The stock’s market capitalization is $311.43 million. The firm has a 50-day moving average price of $5.68 and a 200-day moving average price of $6.00.

Sangamo BioSciences (NASDAQ:SGMO) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.14. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.38 million. During the same period in the prior year, the business posted ($0.17) earnings per share. The company’s quarterly revenue was down 56.0% compared to the same quarter last year. On average, equities research analysts expect that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current year.

A hedge fund recently raised its stake in Sangamo BioSciences stock. Royce & Associates LLC raised its position in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned 0.45% of Sangamo BioSciences worth $2,849,000 at the end of the most recent reporting period.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.